(Q42837261)

English

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

scientific article published on 3 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 November 2017

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. (English)

1 reference

Europe PubMed Central

8 November 2017

1 reference

based on heuristic

inferred from title

Jens Juul Holst

15

1 reference

Europe PubMed Central

8 November 2017

object named as

F Liu

11

0 references

Carolyn F. Deacon

object named as

C Deacon

16

0 references

author name string

E M Migoya

1

1 reference

Europe PubMed Central

8 November 2017

R Bergeron

2

1 reference

Europe PubMed Central

8 November 2017

J L Miller

3

1 reference

Europe PubMed Central

8 November 2017

R N K Snyder

4

1 reference

Europe PubMed Central

8 November 2017

M Tanen

5

1 reference

Europe PubMed Central

8 November 2017

D Hilliard

6

1 reference

Europe PubMed Central

8 November 2017

B Weiss

7

1 reference

Europe PubMed Central

8 November 2017

P Larson

8

1 reference

Europe PubMed Central

8 November 2017

M Gutierrez

9

1 reference

Europe PubMed Central

8 November 2017

G Jiang

10

1 reference

Europe PubMed Central

8 November 2017

K A Pryor

12

1 reference

Europe PubMed Central

8 November 2017

J Yao

13

1 reference

Europe PubMed Central

8 November 2017

L Zhu

14

1 reference

Europe PubMed Central

8 November 2017

G Herman

17

1 reference

Europe PubMed Central

8 November 2017

N Thornberry

18

1 reference

Europe PubMed Central

8 November 2017

J Amatruda

19

1 reference

Europe PubMed Central

8 November 2017

D Williams-Herman

20

1 reference

Europe PubMed Central

8 November 2017

J A Wagner

21

1 reference

Europe PubMed Central

8 November 2017

R SinhaRoy

22

1 reference

Europe PubMed Central

8 November 2017

language of work or name

0 references

publication date

3 November 2010

1 reference

Europe PubMed Central

8 November 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

8 November 2017

88

1 reference

Europe PubMed Central

8 November 2017

6

1 reference

Europe PubMed Central

8 November 2017

801-808

1 reference

Europe PubMed Central

8 November 2017

https://scigraph.springernature.com/pub.10.1038/clpt.2010.184

0 references

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Global and societal implications of the diabetes epidemic

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Rationale and options for combination therapy in the treatment of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

The insulin glargine dilemma: an opportunity for the diabetes community?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

Comparing individual means in the analysis of variance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

21 January 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Achieving glycemic goals in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2010.184

1 reference

Europe PubMed Central

8 November 2017

Dimensions Publication ID

0 references

release_ciqldvxbgvfktgnzeq6g7gjmci

1 reference

https://api.fatcat.wiki/v0/release/ciqldvxbgvfktgnzeq6g7gjmci

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

8 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42837261&oldid=1836244562"